Back to Results

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Breelyn Wilky

Breelyn Wilky

Study ID

Protocol Number: 20-2042

More information available at ClinicalTrials.gov: NCT03860272

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers